19104514 |
Targeting cancer with small molecule kinase inhibitors
Zhang, J,
Yang, PL,
Gray, NS
|
Nat. Rev. Cancer |
2009 |
22089421 |
Gastrointestinal stromal tumours: origin and molecular oncology
Barnett, CM,
Corless, CL,
Heinrich, MC
|
Nat. Rev. Cancer |
2011 |
16783341 |
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y,
Gray, NS
|
Nat. Chem. Biol. |
2006 |
25239608 |
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
Anjum, R,
Heinrich, MC,
Ketzer, J,
Bauer, S,
Zhu, M,
Zhou, T,
Serrano, C,
Song, Y,
Fletcher, JA,
Schrock, A,
Ning, Y,
Eilers, G,
Wardwell, S,
Gozgit, JM,
Kohlmann, A,
Garner, AP,
Rivera, VM,
Vodala, S,
Clackson, T,
Wang, F
|
Clin. Cancer Res. |
2014 |
28478525 |
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors
Morales-Barrera, R,
Carles, J,
Suárez, C,
García-Valverde, A,
Olivares, D,
Valverde, C,
George, S,
Serrano, C
|
Target Oncol |
2017 |
29704617 |
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
Roskoski, R
|
Pharmacol. Res. |
2018 |
15010069 |
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
Sciot, R,
Debiec-Rychter, M,
van Glabbeke, M,
Stul, M,
Dumez, H,
van Oosterom, AT,
EORTC Soft Tissue and Bone Sarcoma Group, -,
Verweij, J,
Judson, I,
Hagemeijer, A,
Brown, M,
Vranck, H,
Wasag, B,
Dimitrijevic, S,
Scurr, M
|
Eur. J. Cancer |
2004 |
30792533 |
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Heinrich, MC,
Ketzer, J,
Bauer, S,
Zhu, M,
Presnell, A,
Raut, CP,
George, S,
Mannan, AM,
Serrano, C,
Yu, C,
Sicinska, E,
Tao, DL,
Rubin, BP,
Fletcher, JA,
Mariño-Enríquez, A,
Demetri, GD,
Eilers, G,
Czaplinski, JT,
McKinley, A
|
Br. J. Cancer |
2019 |
29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Heinrich, MC,
Kent, JD,
Klug, LR
|
Pharmacol. Ther. |
2018 |